
BAMF Health Doses First Patient in the U.S. in Phase 2b Imaging Study of Brain Metastasis
BAMF Health dosed the first patient in the U.S. for Radiopharm Theranostics’ Phase 2b imaging study of 18F-RAD101 in suspected recurrent brain metastasis.
April 28, 2025